Scholarlink

<p>Epigenetic modifications are dynamic and reversible, making them attractive targets for therapeutic intervention in cancer. Although several drugs targeting epigenetic modifications (epidrugs) have been clinically approved, their application in T-cell acute lymphoblastic leukemia (T-ALL) remains limited, and predictive biomarkers of response are lacking. Here, we present a mass spectrometry (MS)-based pharmacoepigenetic approach to profile histone post-translational modifications (hPTMs) to identify signatures associated with drug sensitivity in T-ALL . Baseline hPTM landscapes were previously established by our group for 21&#xa0;T-ALL cell lines using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Here, we treated these cell lines with a panel of nine drugs including histone deacetylase inhibitors and DNA methyltransferase inhibitors (epidrugs), alongside anthracyclines, which were included due to their known chromatin-related effects. Correlation of cell viability data with hPTM levels revealed distinct hPTM signatures linked to sensitivity for each drug class. These signatures were subsequently evaluated in T-ALL patient-derived xenograft (PDX) models. However, our analysis revealed substantial discrepancies in hPTM sensitivity signatures compared to those observed in vitro. Co-variation network analysis highlighted divergence in hPTM-hPTM correlation between the two models, underscoring limitations of cell lines for modeling dynamic epigenetic regulation in vivo. Our findings establish a framework for MS-based hPTM profiling in T-ALL and emphasize the importance of model selection in developing predictive epigenetic biomarkers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Laura Corveleyn,
  • Lien Provez,
  • Osman Satilmis,
  • Nina Refhagen,
  • Mattias Landfors,
  • Wouter Sleeckx,
  • Beatrice Lintermans,
  • Amélie De Maesschalck,
  • Rishi S. Kotecha,
  • Barbara De Moerloose,
  • Tim Lammens,
  • Dieter Deforce,
  • Sofie Degerman,
  • Steven Goossens,
  • Pieter Van Vlierberghe,
  • Maarten Dhaenens

摘要

Epigenetic modifications are dynamic and reversible, making them attractive targets for therapeutic intervention in cancer. Although several drugs targeting epigenetic modifications (epidrugs) have been clinically approved, their application in T-cell acute lymphoblastic leukemia (T-ALL) remains limited, and predictive biomarkers of response are lacking. Here, we present a mass spectrometry (MS)-based pharmacoepigenetic approach to profile histone post-translational modifications (hPTMs) to identify signatures associated with drug sensitivity in T-ALL . Baseline hPTM landscapes were previously established by our group for 21 T-ALL cell lines using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Here, we treated these cell lines with a panel of nine drugs including histone deacetylase inhibitors and DNA methyltransferase inhibitors (epidrugs), alongside anthracyclines, which were included due to their known chromatin-related effects. Correlation of cell viability data with hPTM levels revealed distinct hPTM signatures linked to sensitivity for each drug class. These signatures were subsequently evaluated in T-ALL patient-derived xenograft (PDX) models. However, our analysis revealed substantial discrepancies in hPTM sensitivity signatures compared to those observed in vitro. Co-variation network analysis highlighted divergence in hPTM-hPTM correlation between the two models, underscoring limitations of cell lines for modeling dynamic epigenetic regulation in vivo. Our findings establish a framework for MS-based hPTM profiling in T-ALL and emphasize the importance of model selection in developing predictive epigenetic biomarkers.